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introduction: Presently used radiochemotherapy regimens result in moderate local 
control rates for patients with advanced head-and-neck squamous cell carcinoma 
(HNSCC). Dose escalation (DE) may be an option to improve patient outcome, but may 
also increase the risk of toxicities in healthy tissue. The presented treatment planning 
study evaluated the feasibility of two DE levels for advanced HNSCC patients, planned 
with either intensity-modulated photon therapy (IMXT) or proton therapy (IMPT).
Materials and methods: For 45 HNSCC patients, IMXT and IMPT treatment plans 
were created including DE via a simultaneous integrated boost (SIB) in the high-risk 
volume, while maintaining standard fractionation with 2 Gy per fraction in the remaining 
target volume. Two DE levels for the SIB were compared: 2.3 and 2.6 Gy. Treatment plan 
evaluation included assessment of tumor control probabilities (TCP) and normal tissue 
complication probabilities (NTCP).
results: An increase of approximately 10% in TCP was estimated between the DE 
levels. A pronounced high-dose rim surrounding the SIB volume was identified in IMXT 
treatment. Compared to IMPT, this extra dose slightly increased the TCP values and to 
a larger extent the NTCP values. For both modalities, the higher DE level led only to a 
small increase in NTCP values (mean differences <2%) in all models, except for the risk 
of aspiration, which increased on average by 8 and 6% with IMXT and IMPT, respectively, 
but showed a considerable patient dependence.
conclusion: Both DE levels appear applicable to patients with IMXT and IMPT since all 
calculated NTCP values, except for one, increased only little for the higher DE level. The 
estimated TCP increase is of relevant magnitude. The higher DE schedule needs to be 
investigated carefully in the setting of a prospective clinical trial, especially regarding toxici-
ties caused by high local doses that lack a sound dose–response description, e.g., ulcers.
Keywords: photon radiotherapy, proton radiotherapy, tumor control probability, normal tissue complication 
probability, head-and-neck cancer
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inTrODUcTiOn
Standard of care for inoperable advanced head-and-neck 
squamous cell carcinoma (HNSCC) patients is concurrent 
radiochemotherapy, which today is still associated with a 
substantial recurrence rate (1, 2). Thus, an improvement of 
treatment outcome is desirable. Radiotherapy intensification to 
the primary tumor volume may improve patient outcome, since 
most recurring HNSCC after radiotherapy develop at the site of 
the initial primary tumor volume (3–5). Treatment intensifica-
tion with radiation dose escalation (DE) is possible by applying 
non-uniform dose distributions. The simultaneous integrated 
boost (SIB) technique exploits the advantage of maintaining 
the treatment time  –  a critical factor in HNSCC radiotherapy 
(6–10). Radioresistant tumors may increasingly be identified 
by molecular profiling (11, 12), and radioresistant sub-regions 
within individual tumor volumes may be identified with func-
tional imaging such as positron emission tomography (PET) (13, 
14). Several groups have proposed dose painting of sub-volumes 
using hypoxia imaging with fluoromisonidazole (FMISO) PET 
(15–18). Since the capability of the dose painting approach to 
increase local tumor control is controversial, another approach 
is DE on the whole tumor volume (19, 20). However, treatment 
intensification may lead to an increase in side effects. Accordingly, 
higher dose conformity with proton therapy (PT) compared to 
advanced photon therapy (XT) may be beneficial. To estimate the 
overall benefit of treatment intensification, the probable gain in 
tumor control needs to be balanced against a potential increase in 
toxicity risk. This can be done in the treatment planning stage by 
comparing the resulting differences in tumor control probability 
(TCP) with those in normal tissue complication probability 
(NTCP).
Inhomogeneous dose prescriptions [e.g., different doses to 
gross tumor volume (GTV) and elective tumor volume] are 
driven by the clinical experience of a spatially heterogeneous 
dose–response in the target volume. Therefore, realistic modeling 
of TCP has to allow for dosimetric as well as radiobiological het-
erogeneity within the target. A recently presented TCP approach 
(21) provides dose–response relations for each of the considered 
target sub-volumes that base on clinical outcome data on the 
recurrence distribution in the tumor volume [e.g., Ref. (22)]. In 
contrast, if a homogeneous dose–response in the entire target vol-
ume was assumed, TCP estimates would suggest a low probability 
of treatment failures in the high-risk tumor sub-volume and most 
failures in the low-dose elective sub-volume (21), contradicting 
clinically observed data on failure patterns.
Regarding NTCP, in a previous work, we identified locally 
advanced HNSCC patients with substantial benefit from PT 
by comparing intensity-modulated XT (IMXT) with intensity-
modulated PT (IMPT), focusing on patient sub-groups with 
similar primary tumor location (23). Therein, IMPT compared to 
IMXT showed the general capability to reduce NTCP. Moreover, 
we estimated the benefit of a mixed modality treatment (IMXT 
followed by IMPT for sequential boost treatment) by considering 
the NTCP reduction compared to IMXT alone revealing a minor 
effect in most of the patient cases (24). Following these studies, 
a prospective multi-centric clinical study is currently planned in 
our institution aiming at the evaluation of the effect of a 2.3 Gy 
DE in the treatment of advanced HNSCC.
In the present in  silico study, we assessed the feasibility of a 
fractionation schedule for further treatment intensification via 
the SIB technique with a DE level of 2.6 Gy in comparison to the 
2.3 Gy DE level applied in the previous work. We estimated TCP 
for these two DE levels and set the expected gain in relation to a 
potential increase in NTCP values.
MaTerials anD MeThODs
Patient Data, Treatment schedule, Volume 
Definition, Treatment Planning
Computed tomography (CT) and fluorodeoxyglucose (FDG) 
PET datasets of 45 patients treated between 2006 and 2013 at 
the University Hospital Dresden, Germany were available for the 
present analysis. Datasets consisted of a pre-treatment FDG PET/
CT and a sequential FDG PET/CT recorded after approximately 
20 fractions. All patients gave written consent for the use of their 
data. The study was approved by the institutional Ethics commit-
tee. A treatment schedule was defined that consists of two main 
treatment series planned on two different CT datasets: series I, 
a treatment series of 25 fractions for the elective clinical target 
volume (CTVelec), was planned on a baseline CT with 2 Gy per 
fraction plus a SIB starting at the eleventh fraction allowing for 
a hypoxia PET stratification based on a scan during treatment. 
This SIB volume (GTVSIB-I) was either defined as the GTV or, 
in the case of N3 status, as GTV and the N3 lymph nodes. A 
CTVgross-I was generated by isotropic extension of 5–10 mm of the 
GTVSIB-I and corrected for air cavities and bones if not infiltrated. 
Series II, a sequential boost of 11 fractions, was planned on a 
sequential PET/CT dataset taken after 20 treatment fractions. A 
dose of 2 Gy per fraction was prescribed to the CTV consisting 
of a geometrical expansion of the GTV and suspect lymph nodes 
(CTVgross-II). Additionally, the sequential boost contained a SIB to 
FDG-avid volumes inside the GTV identified on the FDG–PET 
scan after 20 treatment fractions (GTVSIB-II). Planning target 
volumes (PTV) were created for the CTV expanding 5 mm in 
cranio-caudal direction and 4  mm in plane, retaining a 3  mm 
distance to the external patient contour. Prescribed dose levels 
were 50 Gy to the CTVelec, 72 Gy to the CTVgross and 79.8 Gy (DE1) 
or 87.6 Gy (DE2) to the SIB volume, depending on the DE level. 
The equivalent dose in 2 Gy fractions (EQD2) in the SIB volume 
was 81.3 Gy and 91.0 Gy, respectively, assuming an α/β ratio of 
10 Gy. A constant correction factor of 1.1 was used for the higher 
relative biological effectiveness (RBE) of protons compared to 
photons, such that all values given in Gy actually mean Gy(RBE) 
for IMPT. Delineated organs at risk (OAR) were spinal cord, brain 
stem, ipsi- and contralateral parotid gland, ipsi- and contralateral 
brachial plexus, mucosa, swallowing muscles, larynx, esophagus, 
mandible, ipsi- and contralateral temporomandibular joints, ipsi- 
and contralateral submandibular and sublingual glands.
Intensity-modulated photon therapy treatment plans were 
based on seven equidistant 6 MV photon beams. A field reduction 
to five beams was considered for Series II for one-sided sequential 
boost volumes. IMPT treatment plans were based on a three field 
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beam arrangement with beam angles of −40°, 40°, and 180°, but 
changes of these angles were possible for one-sided sequential 
boost volumes in Series II. Optimization goals for target struc-
tures were to irradiate at least 95% of the target volumes (PTVelec, 
PTVgross, GTVSIB) above 95% of the prescribed dose (V95 > 95%). 
Furthermore, volumes above 107% (V107) of the prescribed dose 
should be minimized. Such high-dose volume was accepted in the 
PTV if these were required to ensure the V95 in the GTVSIB. OAR 
constraints with priority over target goals were defined for spinal 
cord (Dmax <  45  Gy), brain stem (Dmax <  54  Gy), and brachial 
plexus (Dmax < 72 Gy). To ensure that these constraints are met 
despite possible positioning uncertainties, the optimization was 
performed for these OARs with an additional margin of 3 mm 
considering the same dose constraint (brain stem and brachial 
plexus) or a slightly increased dose constraint (Dmax < 48 Gy for 
spinal cord). For other OARs, doses were to be minimized without 
compromising target coverage. A more detailed description of the 
patient characteristics, treatment schedule, target definition, and 
treatment planning is presented in Jakobi et al. (23).
Physical Dose evaluation, TcP and nTcP 
Modeling
Dose parameters in the PTV and GTVSIB were evaluated sepa-
rately for both treatment series. For dose gradient evaluation, a 
relative dose distribution was created by normalizing each voxel 
to its prescribed target dose, as schematically shown in Figure 1A 
for the low DE level of 2.3 Gy. The dose was cumulated from both 
treatment series with a deformable image registration (DIR) on the 
pre-treatment CT and used to estimate TCP and NTCP. The DIR 
was validated in a previous study (25). In the target volume, the 
fractionation effect was considered by voxel-wise calculation of 
EQD2 (α/β = 10 Gy). For evaluation of NTCP, fractionation effect 
corrections were performed depending on model requirements.
Tumor control probabilities modeling with local control as 
endpoint was based on an approach described by Lühr et  al. 
[abstract in Ref. (21)]. This approach considers that the target 
volume consists of disjoint sub-volumes (schematically depicted 
in Figure 2), which differ in dose–response. The target structures 
CTVelec, CTVgross, and GTVSIB were considered as target sub-
volumes. To ensure that all sub-volumes were disjoint, inner 
sub-volumes were excluded from outer sub-volumes (e.g., GTVSIB 
from CTVgross). According to clinically observed spatial failure 
patterns and the dose–response of a comparable patient cohort, 
the model approach assigns different dose–response curves to 
each sub-volume (cf. Figure 2) – each curve specified by its values 
for D50, the dose that yields a TCP of 50%, and γ50, the steep-
ness of the TCP curve at the dose D50. In this study, the overall 
dose–response for homogeneous irradiation was approximated 
by D50 = 70 Gy and γ50 = 1.5 – assuming patients with advanced 
HNSCC – and by the relative proportions of local failures f = 0.80, 
0.18, and 0.02 in GTVSIB, CTVgross, and CTVelec, respectively (22, 
26). The D50 and γ50 parameters resulting from the sub-volume 
TCP approach (assuming the Poisson TCP model) for the three 
considered sub-volumes are listed in Table 1. TCP calculations 
were performed within the modeling framework of the recently 
developed ReCompare (REmote COMparison of PARticlE and 
photon plans) tool (27, 28).
Normal tissue complication probabilities values were calcu-
lated using recently published models for the following toxicities 
FigUre 1 | relative dose distributions. (a) Illustration of calculating the voxel-wise relative dose distribution, exemplarily for DE level of 2.3 Gy. For the high DE 
level, the SIB volume is normalized to 2.6 Gy in the same way. (B) Relative dose distribution in the elective target only showing high-dose areas outside ICRU 
constraints (>107%). All four SIB treatment plans for one patient are shown for series I treatment, illustrating the larger high-dose rim around the SIB volume for the 
high DE level of 2.6 Gy. PTVelec is outlined in black, GTVSIB-I in yellow.
FigUre 2 | schematic drawing of the sub-volume TcP model approach. Empirical dose–response data from comparable patient cohorts – given as (a) 
dose–response curve and (B) spatial distribution of local failures (represented by the asterisks) – serve as input to generate (c) one dose–response curve for each 
target sub-volume. The total TCP results from the product of all sub-volume TCP. Note, all target sub-volumes have to be disjoint. Therefore, inner sub-volumes are 
excluded from outer encompassing structures.
TaBle 1 | TcP model parameters determining the dose–response in the 
target sub-volumes.
sub-volume D50/gy γ50/%/% f
Total 70.00a 1.50a 1.00
GTVSIB 66.79 1.43 0.80a
CTVgross 40.36 0.86 0.18a
CTVelec 6.73 0.14 0.02a
They base on empirical total TCP parameters (D50, γ50) and on observed failure 
proportions f and were determined according to the sub-volume TCP approach.
aValues served as input data for the sub-volume model parameters D50 and γ50.
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and endpoints: incidence of acute oral mucositis (grade ≥3); 
aspiration assessed by videofluoroscopy; xerostomia in terms of 
salivary flow reduction 12 months after therapy; subjective and 
objective swallowing dysfunctions; incidence risk of late larynx 
edema (grade ≥2); and trismus (jaw-opening <35 mm). Details 
on the model parameters can be found in Ref. (29–34) and as 
an overview in Jakobi et al. (23). Modeling the risk of a specific 
toxicity in a patient was skipped when a substantial portion of 
the NTCP-relevant organ was infiltrated by the tumor (physician’s 
decision).
To estimate the relative effect of the treatment intensification 
on tumor control and toxicity, individual patient matched-pair 
analyses of TCP and NTCP values were performed between 
the two different DE levels: ΔTCP  =  TCPDE2  −  TCPDE1 and 
ΔNTCP = NTCPDE2 − NTCPDE1. The evaluation was carried out 
separately for IMXT and IMPT. Statistically significant differences 
between the DE levels were tested by two-sided paired t-tests with 
TaBle 2 | Mean (±1 sD) total and tumor sub-volume TcP values (upper 
rows) and nTcP values of the evaluated models (lower rows) for the two 
De levels and both treatment modalities.
iMXT iMPT
TcPDe1/% TcPDe2/% TcPDe1/% TcPDe2/%
Total 66.3 ± 0.9 75.9 ± 1.3 65.5 ± 0.8 74.8 ± 1.3
GTVSIB 73.7 ± 0.8 83.2 ± 1.2 73.5 ± 0.9 83.1 ± 1.2
CTVgross 92.2 ± 0.6 93.3 ± 1.0 91.7 ± 0.5 92.7 ± 1.0
CTVelec 97.7 ± 0.4 97.7 ± 0.4 97.1 ± 0.5 97.1 ± 0.5
nTcPDe1/% nTcPDe2/% nTcPDe1/% nTcPDe2/%
Oral mucositis 45.8 ± 9.0 46.2 ± 9.2 40.0 ± 12.4 40.2 ± 12.5
Xerostomia 20.5 ± 10.9 20.6 ± 11.2 6.7 ± 4.6 6.7 ± 4.6
Aspiration 57.5 ± 23.2 65.8 ± 23.4 37.5 ± 25.1 43.8 ± 26.8
Dysphagiaa 47.5 ± 11.4 49.5 ± 11.9 36.7 ± 13.1 37.7 ± 13.5
Swall. Solidsb 34.4 ± 9.7 36.6 ± 10.5 25.7 ± 10.9 26.6 ± 11.4
Swall. Liquidsb 10.3 ± 4.4 11.4 ± 5.2 9.0 ± 4.7 9.5 ± 5.1
Larynx edema 77.8 ± 25.0 79.0 ± 24.9 64.6 ± 36.9 65.4 ± 37.0
Trismus 30.9 ± 5.7 31.0 ± 5.8 26.0 ± 3.7 26.0 ± 3.8
aPhysician-rated swallowing dysfunction.
bPatient-rated swallowing problems of different severity.
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a significance level of 0.05. We analyzed the sensitivity of the TCP 
results by quantifying the dependence of ΔTCP on the input 
parameters D50 and γ50 for a homogeneous dose–response. One 
of the two input parameters was kept at its nominal value (70 Gy 
and 1.5, respectively) while the other parameter was varied within 
a certain range: 60 Gy ≤ D50 ≤ 80 Gy and 0.5 ≤ γ50 ≤ 3.0.
resUlTs
Target Dose evaluation
Dose coverage of the respective PTV (PTVelec, PTVsequential boost) 
and GTVSIB structures (GTVSIB-I, GTVSIB-II) evaluated with V95 
was similar for both DE schedules, independent of the treatment 
modality. The pursued minimum criterion (V95 > 95%) was ful-
filled in all cases (IMXT and IMPT) except for V95 of GTVSIB-II in 
both DE levels for one patient with a tumor close to a prioritized 
organ (brachial plexus).
High-dose volumes, evaluated by V107 in a structure composed 
of the respective PTV excluding the respective GTVSIB, the latter 
expanded by 5 mm, showed a significant increase between the two 
DE levels. For IMXT treatment, the mean patient-wise difference 
(±SD) V107,DE2 − V107,DE1 = 4.4 (±3.9)% (p < 0.001) is much larger 
than for IMPT with V107,DE2 − V107,DE1 = 0.1 (±1.6)% (p = 0.004). 
This is illustrated in Figure 1B by the relative dose distribution 
showing a large increase in dose above 107% surrounding the 
GTVSIB-I for IMXT, while the increase for IMPT is small. V107 of 
the GTVSIB was 0% in 44 of 45 patients.
evaluation of TcP
Mean TCP values for all 45 HNSCC patients are given in the 
upper part of Table 2 for both DE levels. Significant differences 
between the two DE levels exist for all evaluated target structures 
for both modalities (p <  0.001). TCP values decreased from 
CTVelec to CTVgross-I to GTVSIB-I, i.e., from the outer to the inner 
target sub-volumes. The higher DE level led to a relevant increase 
in TCP values for the GTVSIB-I (9.6% for both modalities) and 
the total TCP (9.6% with IMXT, 9.3% with IMPT), while the 
differences for CTVgross-I and CTVelec were small with mean dif-
ferences of 1 and 0%, respectively, independent of the treatment 
modality (Figure 3A). This was expected since the DE with the 
SIB technique focused on the GTV, while the dose to CTVelec and 
CTVgross-I was targeted to remain stable between both DE levels. 
The small differences in TCP values for the CTVgross-I between 
the DE levels resulted from the increase in dose that spilled 
out of the GTV into the surrounding CTVgross-I. TCP values for 
IMXT were in general slightly larger than for IMPT. This resulted 
from increased dose in the target regions around the GTVSIB-I 
for IMXT, caused by its less conformal dose distribution of the 
integrated boost.
The estimated absolute TCP values depended on the employed 
model parameters. The mean increase in TCP from DE1 to DE2 
was rather robust against the variation of the model parameters 
D50 and γ50 in intervals clinically reasonable for advanced HNSCC 
(Figure 4). For example, halving and doubling the slope param-
eter γ50 from a nominal value of 1.5–0.75 and 3 reduced the mean 
ΔTCP by about 0.03 and by 0.002, respectively. In comparison, 
the dependence of ΔTCP on D50 was stronger and the estimated 
gain in TCP between the DE levels increased monotonously for 
more radioresistant tumors (higher D50). The ΔTCP variation was 
very similar for IMXT and IMPT.
evaluation of nTcP
Mean NTCP values for all 45 HNSCC patients are given in the 
lower part of Table 2 for both DE levels. Absolute NTCP values 
were patient dependent and toxicity dependent. The integral dose 
in the patient external contour outside the target volume did not 
increase with the DE level. Similarly, dose to the OARs were in 
most cases only slightly increased. As a consequence, the influ-
ence of the DE level on NTCP values was almost negligible in 
most of the evaluated NTCP models with mean ΔNTCP values of 
approximately 1%. Only the risk of aspiration, modeled with the 
dose to the pharyngeal constrictor muscle (PCM), was substan-
tially increased from DE1 to DE2 by on average (±SD) 8 (±4)% 
(p < 0.001) for all patients with IMXT and 6 (±4)% (p < 0.001) 
with IMPT (Figure 3B).
Additionally, the analysis revealed that all NTCP values for 
IMXT were larger than for IMPT (p <  0.001 for all evaluated 
models), especially for the risk of xerostomia and aspiration. 
This reflects the ability of IMPT to create more conformal dose 
distributions compared to IMXT. As a result, the ΔNTCP were 
also smaller in most cases for IMPT.
DiscUssiOn
We conducted an analysis of the effect of DE for 45 HNSCC 
patients by comparing TCP and NTCP values of two different 
dose levels for IMXT as well as IMPT treatment in an in  silico 
study. DE applied by the SIB technique allows for a confined 
treatment intensification focusing on the region of highest risk 
for recurrence with both, IMXT and IMPT. This is reflected by 
the estimated TCP values, which clearly increased for the GTV 
FigUre 4 | Dependence of the difference in total tumor control probability ΔTcP between the two dose escalation levels on the model input 
parameters (a) D50 and (B) γ50. Results are shown for IMXT and IMPT plans. The enlarged symbols mark the parameter values used in this study.
FigUre 3 | estimated differences between the two dose escalation levels for iMXT and iMPT: (a) ΔTcP and (B) ΔnTcP. MUC, oral mucositis; X12, 
xerostomia after 12 months; ASP, aspiration; DYS, physician-rated swallowing dysfunction; SWS, patient-rated problems with swallowing solids; SWL, patient-rated 
problems with swallowing liquids; LOE, laryngeal edema; TRI, trismus.
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(the targeted region for treatment intensification) while the 
values remained almost unchanged for the surrounding target 
volumes, CTVgross and CTVelec. Similarly, the dose to surrounding 
healthy tissues was only marginally increased for the higher DE 
level and the difference in NTCP values was practically negligible 
for all considered toxicities except for aspiration. The increase of 
estimated NTCP for aspiration resulted primarily from higher 
maximum doses in the PCM, since the model for aspiration 
uses a generalized equivalent uniform dose (gEUD) as input that 
is close to the maximum dose. Thus, an increase of high doses 
even in a small localized region of the PCM has a large impact 
on the NTCP value estimated by the employed aspiration model. 
Accordingly, setting a specific dose constraint for this organ in the 
treatment plan optimization may be appropriate in a DE study. 
All other employed NTCP models are based on mean organ 
dose as gEUD (or close to that) and their NTCP values were less 
sensitive to changes in local dose, leading to the observed small 
ΔNTCP values.
Treatment plans for PT possessed steeper dose gradients 
leading to a reduced high-dose spill into the tissue surrounding 
the SIB volume (high-dose rim) compared to IMXT plans. As a 
result, the ΔNTCP values were larger for IMXT than for IMPT. 
Also ΔTCP was slightly enhanced with IMXT for the two CTV 
sub-volumes. This difference in dose conformity together with 
the already lower NTCP level for IMPT let IMPT appear as a 
potential option for DE treatment in selected cases where IMXT 
leads to an unacceptable increase of NTCP values. However, 
for the lower DE level, DE1, with 2.3 Gy per fraction in the SIB 
volume (i.e., close to 2  Gy), the spill-over dose that increased 
the V107 in the CTV was still comparable between IMXT and 
IMPT. Thus, for such a low DE level the spill-over dose similarly 
affects the increase in toxicity risk for both treatment modalities. 
The small extent of spill-over for DE1 can be explained by the 
allowed dose variation in the two target volumes from 95% up 
to 107% of the prescribed dose, which is considered acceptable 
according to constraints of the International Commission on 
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Radiation Units and Measurements (ICRU) (35). For example, a 
dose level of 2.3 Gy in the SIB volume requires (V95) a minimum 
of 2.19 Gy, while 2 Gy in the surrounding CTV permits (V107) a 
maximum of 2.14 Gy. Thus for DE1, both allowed dose limits are 
close together.
Based on the evaluated increase in toxicity risk via NTCP, a 
DE with a SIB of 2.6  Gy seems as feasible as a 2.3  Gy SIB for 
both modalities. Only for one toxicity endpoint (aspiration), an 
increase in risk was predicted by the NTCP models. At the same 
time, the expected benefit of the higher DE was a gain of about 
10% in TCP which may be even higher for more radioresistant 
tumors (higher D50). The NTCP increase in aspiration of about 
the same magnitude is of clinical concern, as aspiration pneu-
monia may be the consequence and thus might be unacceptable 
in this relation, calling for a well-chosen dose limit for the PCM. 
The overall small increase in toxicity risk for most models for 
the evaluated DE level is in accordance with other published 
studies. Isotoxic DE from 70 Gy to comparable dose levels was 
rated feasible with a SIB in a small treatment planning study by 
Thorwarth et al. (36), where a DE of 50% (DE2 in the present 
study would corresponds to about 25%) was assessed as upper 
limit by evaluation of dosimetric data for a smaller number of 
OARs. Leclerc et al. (37) demonstrated the clinical applicability of 
a SIB with 2.5 Gy per fraction in a multi-centric phase I–II study, 
however, with a reduced total dose of 75 Gy (EQD2 = 78.1 Gy) 
and less advanced tumor stages.
This is the first study that employs the sub-volume TCP model 
to analyze the potential gain of different DE levels limited to a 
high-risk target sub-volume. The approach builds on established 
empirical knowledge on dose–response for homogeneous dose 
irradiation and corresponding spatially heterogeneous patterns 
of treatment failures. Recently, Vogelius et al. used a conceptually 
similar approach to analyze the potential of a data-driven dose-
painting strategy for HNSCC (38). Assuming D50 to be close to 
60.5 Gy, they found a substantial increase in local control with an 
estimated TCP of 89% for spatially optimized dose prescriptions. 
Considering the same D50 parameter, this TCP value is in good 
agreement with a TCP of about 87% estimated with the approach 
of the current study for the high DE level DE2. An ongoing Danish 
clinical trial that tests the data-driven dose-painting approach is 
supposed to provide clinical evidence that further supports the 
used TCP model.
Normal tissue complication probability evaluation was 
restricted to published toxicity models. The only toxicity, for which 
an increased risk of NTCP was found, differed from the others in 
modeling by being sensitive to local high-dose levels. This may 
also occur for other dose limiting toxicities, e.g., for ulceration of 
tissue, which was shown to be sensitive to high local doses within 
small volumes (39). Treatment planning studies evaluating the 
feasibility of DE in the view of potential side effects are limited to 
known dose–response effects and are a first step allowing for an 
ethically justifiable clinical trial. Thus, the theoretical feasibility 
of the DE schedule, demonstrated with the presented treatment 
planning study, needs to be carefully validated in a clinical setting.
A limitation of the presented analysis is the use of nomi-
nal dose distributions. As Müller et  al. (40) and Góra et  al. 
(41) showed, IMPT treatment plans are more prone to dose 
distortions originating from anatomical changes of the patients. 
Such changes can decrease the dose conformity to the target 
volume and thus deteriorate the TCP. Furthermore, they can 
result in increased dose to nearby healthy tissues, increasing the 
NTCP. The presented treatment planning study design included 
a one-step adaptation strategy to reduce the effects of patient 
anatomy changes on the dose distribution. Changes in anatomy 
would impose in a similar way on the dose distributions of the 
two compared DE levels, reducing their effect on the differences 
evaluated in the present study. However, the adaptation approach 
introduces an additional uncertainty by using a DIR for dose 
accumulation. Again, this uncertainty affects both DE levels in a 
similar way, reducing its influence on the difference values. In a 
clinical setting, close consideration is required to limit the effect 
of anatomical changes, e.g., by implementing plan adaptation 
protocols.
Another limitation originates from uncertainties connected 
to the modeling of the TCP and NTCP values. As a consequence, 
the results need to be interpreted carefully, especially, when 
absolute TCP and NTCP values are considered. However, this 
study focused on differences between model values for the two 
DE levels. Such relative results tend to be more robust, as some 
uncertainties may affect the absolute NTCP and TCP values 
in a similar way, having a minor effect on the differences. For 
example, the D50 parameter sensitivity analysis, which covered 
a broad D50 interval  –  i.e., a large range of patient character-
istics –  led to a variation of the absolute TCP on the order of 
35% (e.g., DE1 of IMXT: from 83 to 47%). Evaluating for the 
same data the impact on ΔTCP resulted in a variation of only 
7% (cf. Figure 4). For NTCP values a comprehensive parameter 
sensitivity analysis was beyond the scope of this study. A case 
study for the physician-rated dysphagia model showed that for 
IMXT a doubling or halving of the input parameters led to a 
relative change of mean ΔNTCP of approximately 50%, i.e., from 
2 to 3% and to 1%, respectively. However, absolute NTCP values 
were similar to values found in other publications using these 
models, and thus the model parameters seem to be reliable for 
the presented patient cohort (31, 42). Consequently, even for 
less favorable model parameters (low D50 or γ50), a substantial 
ΔTCP increase of 5% between the DE levels was estimated, 
while ΔNTCP remained at a smaller level in the case study. 
Assuming for the other models an effect of similar magnitude, 
and considering the small NTCP values for most patients, model 
parameter changes would lead to only little changes regarding 
the presented statements.
cOnclUsiOn
The presented in silico study evaluated two treatment intensifi-
cation strategies differing in the SIB dose level to the high-risk 
tumor sub-volume for advanced HNSCC patients. The increase 
of the DE level from 2.3 to 2.6 Gy per fraction was feasible with 
IMXT and IMPT retaining integral dose and NTCP values of 
all but one endpoint. For aspiration, an increase in estimated 
toxicity risk was identified. The relevant increase in TCP 
between the DE levels originated from a higher TCP in the SIB 
volume, which is of the same order of magnitude as the estimated 
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increase in aspiration toxicity and much higher than the increase 
of the other evaluated toxicities. Weighing the large TCP gain 
against the little NTCP increase of all evaluated models, the use 
of the higher DE level may be beneficial from a clinical point of 
view, except for those situations, where aspiration is of clinical 
concern. Since the analysis was restricted to available toxicity 
models, these findings need to be further investigated in pro-
spective clinical studies.
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